Skip to main content
. 2023 Feb 16;11(2):458. doi: 10.3390/vaccines11020458

Figure 6.

Figure 6

Development of a DNA nanocarrier co-encapsulating CpG and doxorubicin for chemoimmunotherapy. The nanoparticle administration offered superior therapeutic outcome due to the synergistic action of the activated antigen presenting cells and cytotoxicity of the chemotherapeutic agent [96]. Reproduced with permissions from Qian Wang et al., ACS Applied Nanomaterials, American Chemical Society, 2022.